ReviewCurrent atherosclerosis reports2025
N-3 Fatty Acids (EPA and DHA) and Cardiovascular Health - Updated Review of Mechanisms and Clinical Outcomes.
Review in Current atherosclerosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Natural Products as Nutritional Supplements in Human Disease Prevention and Management: From Molecular Mechanisms to Clinical Translation.Nutrients · 2026Review
- Gut Microbiome-Hormone Interactions and Precision Fermentation in the Prevention of Early Cardiovascular Risk in Adolescents.International journal of molecular sciences · 2026Review
- Over Half of the United States Population Had an Undesirably Low Omega-3 Index Based on Erythrocyte Membrane Measurements: Results From the Cross-Sectional NHANES From August 2021 to August 2023.Current developments in nutrition · 2026Article
- Fish oil supplements in patients with chronic kidney disease.Clinical kidney journal · 2026Review
- Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Diet, the protective bridge connecting nutrition and cardiovascular health: A review.Food chemistry: X · 2026Review
- Fatty Acids and Their Roles in Cardiac Physiology and Pathology: Mechanistic and Interventional Studies.Nutrients · 2026Review
- Safety of Commercial Cod Products and Potential Impact on Consumers.Foods (Basel, Switzerland) · 2026Article
- Interaction between high-sensitivity C-reactive protein and mean platelet volume for 1-year major adverse cardiovascular events in stable coronary artery disease.Scientific reports · 2026Article
- Skeletal muscle protein turnover and mitochondrial responses to omega-3 fatty acid supplementation: an update.Current opinion in clinical nutrition and metabolic care · 2026Review
- Advances in Decellularization of Fish Wastes for Extracellular Matrix Extraction in Sustainable Tissue Engineering and Regenerative Medicine.Bioengineering (Basel, Switzerland) · 2026Review
- Microbiota-mediated mechanisms of natural products in atherosclerosis: focus on metabolic and inflammatory pathways.Frontiers in endocrinology · 2026Review
- The role of diet in the pathogenesis and management of premature ovarian insufficiency.Frontiers in nutrition · 2026Review
- Docosahexaenoic acid intake and health in adults and older adults: a narrative review of disparities by country income level.Frontiers in nutrition · 2026Review
- Plant-based diets for human health with implications for cardiometabolic health, gut microbiome, and nutritional adequacy.Frontiers in nutrition · 2026Review
- Targeting the cardio-neuro axis through nutrition: inflammatory mechanisms linking cardiovascular and neurodegenerative diseases.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWe synthesize the latest evidence (published 2020 to 2025) on the role of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in cardiovascular health, emphasizing biological mechanisms and key findings from observational studies and clinical trials related to cardiovascular disease (CVD) risk and outcomes. RECENT
findingsEPA and DHA modulate lipid metabolism, inflammation, platelet and endothelial function, the gut-heart axis, ion channels and autonomic function via vagal tone, supporting cardiovascular health. While individual RCTs have produced variable results, updated cohort data and recent meta-analyses consistently link higher intake or circulating levels of EPA and DHA to reduced risk of cardiovascular events. However, evidence from RCTs indicates that high-dose supplementation may be associated with an increase in atrial fibrillation (AF) risk. Evidence supports a role for EPA and DHA in CVD prevention and treatment, with effects influenced by dose, formulation, and individual variability. Moderate intake appears safe and protective, while high dose EPA may offer added benefits in high-risk individuals but also might increase AF risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.